| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Dextranase targets the alpha-(1,6)-glucosidic linkages within the dextran polymer. These bonds are the primary connections between glucose units in the bacterial polysaccharide. The enzyme has an endo-mode of action, randomly cleaving internal bonds to produce smaller dextran fragments. Its substrate specificity is directed toward the glycosidic bonds that contribute to the viscous, sticky properties of dextran.
|
|---|---|
| ln Vitro |
Dextranase activity is measured in vitro by incubating the enzyme with a defined dextran substrate and monitoring the release of reducing sugars. Standard assays use 1% (w/v) dextran (molecular weight 40,000-500,000) in phosphate buffer (50 mM, pH 6.0) at 40degC for 30 minutes. The reaction is stopped by boiling or by adding DNS (3,5-dinitrosalicylic acid) reagent, and the increase in reducing sugar is quantified spectrophotometrically at 540 nm. One unit of activity is defined as the amount of enzyme that releases 1 umol of reducing sugar (expressed as glucose equivalent) per minute under assay conditions.
|
| ln Vivo |
Dextranase is not used for in vivo pharmacological activity studies, as it is an industrial and research enzyme. However, it has been investigated for medical applications, such as enhancing the activity of endocarditis antibiotics by breaking down bacterial biofilms. Dextranase can disrupt dextran-containing biofilms produced by oral bacteria (e.g., Streptococcus mutans) and may have potential in preventing dental plaque. In animal models of infective endocarditis, dextranase has been shown to potentiate the efficacy of antibiotics.
|
| Enzyme Assay |
For non-cellular assays (enzyme activity measurement), a standard protocol is as follows: Dextranase is dissolved in 50 mM sodium acetate buffer (pH 5.0) at a concentration of 0.1-1 U/mL. Substrate solution: 1% (w/v) dextran (MW 500,000) in the same buffer. Mix 0.2 mL of enzyme solution with 0.8 mL of substrate solution and incubate at 40degC for 30 minutes. The reaction is terminated by adding 2 mL of DNS reagent (3,5-dinitrosalicylic acid) and heating in a boiling water bath for 5 minutes. After cooling to room temperature, absorbance is read at 540 nm. A blank is prepared by heat-inactivated enzyme. Reducing sugar content is calculated using a glucose standard curve.
|
| Cell Assay |
For cell-based assays, bacterial biofilms (e.g., Streptococcus mutans) are cultured in 96-well plates in Tryptic Soy Broth with 1% sucrose for 24-48 hours to form mature biofilms. Dextranase (0.1-10 U/mL) is added to the wells and incubated for 1-4 hours at 37degC. Biofilm disruption is quantified by crystal violet staining: wells are washed, stained with 0.1% crystal violet, washed again, and the bound dye is solubilized with 33% acetic acid, then absorbance is read at 590 nm. For spheroid formation, microcarrier beads coated with cells are treated with dextranase (0.5-5 U/mL) for 30-60 minutes to release multicellular 3D spheroids.
|
| Animal Protocol |
For in vivo animal experiments, rat models of infective endocarditis are used. Rats (e.g., Sprague-Dawley) are catheterized and injected with S. aureus or S. mitis to induce endocarditis. Dextranase is administered intravenously at doses of 10-50 U/kg/day for 7-14 days, alone or in combination with antibiotics (e.g., penicillin G). Bacterial counts in vegetations (valvular lesions) are determined by colony-forming unit (CFU) assays. Alternatively, oral dextranase (50-100 U/kg) can be given to rats to study its effects on dental plaque formation.
|
| ADME/Pharmacokinetics |
Dextranase is an enzyme (≈66-70 kDa) that is optimally active at pH 5.0-6.5 and 40-50degC. It is stable in solution at 4degC for short-term storage, but for long-term storage, it should be kept as a lyophilized powder at -20degC. The enzyme is inactivated by heat (boiling). Solubility: soluble in water and dilute buffers. Common metal ions (Ca2+, Mg2+) may not affect activity, but strong chelating agents (EDTA) can stabilize the enzyme by removing inhibitory metals.
|
| Toxicity/Toxicokinetics |
Dextranase is generally considered non-toxic for its intended uses (food processing, research). As an enzyme, it is a protein and may cause allergic reactions in sensitive individuals upon inhalation or skin contact. In animal studies, dextranase is well-tolerated at therapeutic doses with minimal adverse effects. Standard laboratory safety precautions for handling enzymes should be followed (avoid dust generation, use PPE).
|
| References |
[1]. Nayera A M Abdelwahed, et al. Application of statistical design for the optimization of dextranase production by a novel fungus isolated from Red Sea sponge. 3 Biotech. 2014 Oct;4(5):533-544.
|
| Additional Infomation |
Enzyme that hydrolyze dextran into oligosaccharides.
See also: sesquioxanes, Me (note moved to). Dextranase is an enzyme preparation and industrial reagent, not an approved drug. However, it has been investigated for clinical applications, including prevention of dental caries (by disrupting oral biofilms) and as an adjunct therapy for infective endocarditis. It has also been explored for its ability to produce 3D spheroids for drug screening. No FDA-approved drug product containing dextranase as the active ingredient exists. Dextranase is generally recognized as safe (GRAS) for use in food processing applications (e.g., sugar refining to reduce dextran contamination). |
| Molecular Formula |
C6H12O7
|
|---|---|
| Molecular Weight |
196.155
|
| Exact Mass |
904.45
|
| CAS # |
9025-70-1
|
| PubChem CID |
167312536
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
15.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
70
|
| Complexity |
2100
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=CC=C1C2=C(C(=CCC2)N3C4=C(C=C(C=C4)C5=C6C7=CC=CC=C7N(C6=CC=C5)C(=NC(=CCC8=CC=C(C=C8)C9=CC=CC=C9)C1=CCC(C=C1)C1=CCCC=C1)N)C1=CC=CC=C13)C
|
| InChi Key |
IYKSBVLUZFFSST-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C66H56N4/c1-44-17-9-10-22-53(44)54-25-15-29-60(45(54)2)69-61-27-13-11-23-56(61)58-43-52(40-42-63(58)69)55-26-16-30-64-65(55)57-24-12-14-28-62(57)70(64)66(67)68-59(51-38-36-50(37-39-51)48-20-7-4-8-21-48)41-33-46-31-34-49(35-32-46)47-18-5-3-6-19-47/h3,5-7,9-14,16-24,26-32,34-36,38-43,50H,4,8,15,25,33,37H2,1-2H3,(H2,67,68)
|
| Chemical Name |
N'-[1-(4-cyclohexa-1,5-dien-1-ylcyclohexa-1,5-dien-1-yl)-3-(4-phenylphenyl)prop-1-enyl]-4-[9-[6-methyl-5-(2-methylphenyl)cyclohexa-1,5-dien-1-yl]carbazol-3-yl]carbazole-9-carboximidamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0979 mL | 25.4894 mL | 50.9788 mL | |
| 5 mM | 1.0196 mL | 5.0979 mL | 10.1958 mL | |
| 10 mM | 0.5098 mL | 2.5489 mL | 5.0979 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
